The Global NASH Biomarker Market to Surge at CAGR of 21.28% by 2028

Triton Market Research presents the Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market segmented by Industry Verticals (Hospital, Academic Research Key, Pharma & CRO Industry, Diagnostic Lab), Type (Oxidative stress Biomarker, Apoptosis Biomarker, Hepatic fibrosis Biomarker, Serum Biomarker, Other Types), and by Geography (Asia-Pacific, North America, Middle East and Africa, Latin America, Europe). It further discusses the Market Summary, Industry Outlook, Key Insights, Impact of COVID-19, Porter's Five Forces Analysis, Market Attractiveness Index, Vendor Scorecard, Key Market Strategies, Drivers, Restraints, Opportunities, Competitive Landscape, Research Methodology & Scope, Global Market Size, Forecasts & Analysis (2021-2028).

Triton's report estimates the global non-alcoholic steatohepatitis (NASH) biomarker market to advance in revenue at a CAGR of 21.28% during the phase of 2021-2028.

NASH refers to a more severe form of non-alcoholic fatty liver disease, which can develop into disorders like cirrhosis and hepatocellular carcinoma. A NASH biomarker is used in several verticals, including hospitals, diagnostic labs, and pharma, among others.

Factors such as growth opportunities in the developing regions and the surge in awareness pertaining to non-alcoholic fatty liver disease generate new opportunities for the NASH biomarker market. The emerging regions are offering several opportunities to NASH therapeutics manufacturers due to the improvement in healthcare infrastructure, rise in prevalence of NASH, and surge in demand for healthcare services. Along with this, the growing geriatric population in these nations is also likely to surge the need for NASH therapeutics, driving the studied market's growth.

However, the side effects of NASH therapeutics and the unavailability of specialized diagnostic tests for non-alcoholic fatty liver disease are negatively impacting the growth of the NASH biomarker market.

North America holds the largest market for the non-alcoholic steatohepatitis (NASH) biomarker market, and is anticipated to continue its stronghold till 2028. In the United States, the market is primarily driven by the rise in the prevalence of diabetes and obesity among the population. Further, the expected launch of pipeline molecules, along with the early diagnosis of NASH, is another set of factors motivating the NASH biomarker market's growth. Above all, the favorable reimbursement policies in the healthcare sector are also likely to boost the studied market to a growth path across North America.

The key players established in the NASH biomarker market are Siemens Healthineers, Bristol Myers Squibb Company, Allergan, Merck & Co, Novo Nordisk, Zydus Cadila, Gilead Sciences Inc, Novartis AG, AstraZeneca, Genfit SA, Pfizer Inc, Viking Therapeutics, and Madrigal Pharmaceuticals.

The threat of new players in the market is high as several companies focus on conducting clinical trials. Moreover, numerous small and medium players are expected to enter the market by collaborating with larger companies, increasing the threat of new entrants. Furthermore, several new drugs for the treatment of NASH are in the pipeline, with multiple diagnostic tests likely to gain approval. This is estimated to increase the level of competition among existing market players in the next few years.

Triton Market Research
196, wards wharf approach
London E16 2EQ
Phone: +44 7441 911839
Email: sales@tritonmarketresearch.com
Website: https://www.tritonmarketresearch.com/

We are a leading market research company with offices in the UK, providing the best online market research and data search reports to our clients.

This release was published on openPR.